phosphatidylinositol ether lipid analogue

Phosphatidylinositol ether lipid analogues (PIAs) are a class of synthetic small molecules designed to inhibit the Akt (Protein Kinase B) signaling pathway. These compounds function as competitive inhibitors of the pleckstrin homology (PH) domain of Akt, preventing the protein from binding to phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the plasma membrane. This blockade inhibits Akt translocation and activation, thereby suppressing downstream pro-survival and anti-apoptotic signaling. In preclinical models of glioblastoma multiforme (GBM), PIAs have demonstrated the ability to induce apoptosis and act as radiosensitizers, particularly in tumors with mutated or null p53 status. While several analogues such as SH-5 and SH-6 are widely used as research reagents, they have also been investigated as potential therapeutic candidates for malignant gliomas.

Other names

1-L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonateAkt inhibitor PIA